• info@cancerinformation.com.hk
  • 2121 1328
  • facebook


ONX-0801, 卵巢癌治療藥物有突破性研發
08/06/2017

張碧瑜 / 癌症資訊網

 
澳洲每年有1400位女性死於卵巢​癌. 
研究者稱,ONX-0801(一種試驗藥物)是卵巢​癌治療領域的重大研究進展。
 
此藥是過去十年研發中的最大突破。15位患者參加全球首次ONX-0801的臨床試驗,其中7位患者的腫瘤大幅縮減。這些患者預期壽命幾個月,對現存的藥物及治療方案無反應。
 
更激動人心的是,此藥在攜帶卵巢​癌某致病基因的女性中發揮治療藥效。15位測試者的實驗小組中,10位女性中有7位對ONX-0801有反應。
 
ONX-0801偽裝成葉酸,進入癌細胞內,抑制胸苷酸合成酶,這是新型藥物的首次嘗試。此研究的負責人Udai Banerji(英國癌症研究所藥物發展部副部長兼倫敦皇家Marsden NHS基金會副會長)表示,“這是全新的作用機制。”
 
卵巢​癌細胞有異常大量葉酸受體——葉酸受體α,也就是說此療法能有效對抗卵巢​癌細胞。
 
現存的治療方案對卵巢​癌末期患者無效,而服用ONX-0801,伴有極小的副作用,她們可延長半年多的壽命。Banerji表示,“過去十年,這從未實現。”
 
倘若後續臨床試驗的結果和首次試驗的結果相似,ONX-0801可能將應用於卵巢​癌初期。Banerji認為,ONX-0801在此階段藥效發揮更佳。
 
新療法專攻癌細胞,不幹涉健康細胞。這意味著,病患不會遭受化學治療帶來的副作用,如感染、腹瀉、神經損傷及掉髮等。
 
研究者也創建了測試,探測對ONX-0801反應最敏感的細胞。也就是說,醫生能夠識別接受此藥物治療獲益最大的那群女性。Banerji表示,“當然,現在為時尚早,我非常期待這個療法的後期臨床試驗。”
 
卵巢​癌的症狀較模糊,很多患者求醫時,已是癌症晚期。約60%的女性確診時,癌細胞已擴散至全身,無法治愈。
 
癌症協會的報告指出,在澳洲,僅44%的卵巢​癌患者在確診后能存活5年。卵巢​癌症狀包括: 腹脹;食欲不振或很快有飽腹感;尿頻或尿急;背部、腹部或骨盆疼痛;便秘;月經失調;疲憊;消化不良;性行為期間疼痛等。
 
關於卵巢​癌的更多信息,請訪問澳洲癌症協會官網 
http://www.cancer.org.au/about-cancer/types-of-cancer/ovarian-cancer.html
 
Full coverage
 

Biggest ovarian cancer breakthrough in a decade hailed by researchers

The Independent - ‎Jun 2, 2017‎
Experts called results of the early-phase study “exciting” and “promising” after patients who had exhausted all other treatment options showed an impressive response. The drug, known as ONX-0801, was tested in 15 women with advanced ovarian cancer as ...
 

Experimental ovarian cancer treatment looks 'very promising', researchers say

The Guardian - ‎Jun 2, 2017‎
An experimental new treatment for ovarian cancer led to a dramatic shrinking of tumors in a small, early-phase study. Researchers were testing a drug, known as ONX-0801, for safety, but found that tumors in half of the 15 women studied shrank during ...
 

'Biggest breakthrough in 10 years' in treatment of ovarian cancer

Mirror.co.uk - ‎Jun 2, 2017‎
Scientists have made the biggest breakthrough in a decade in the treatment of advanced ovarian cancer . Seven out of 15 women taking new drug ONX-0801 in a trial run by London's Royal Marsden Hospital were told their tumours had shrunk dramatically.
 

ASCO 2017: Ovarian cancer drug delivers 'very promising' results in early trial

The Institute of Cancer Research - ‎Jun 2, 2017‎
A team at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust tested the drug, known in the study as ONX-0801, in 15 women with ovarian cancer as part of a wider phase I clinical trial. Phase I trials are run in ...
 

Ovarian cancer drug hailed as 'biggest breakthrough in a decade'

Sky News - ‎Jun 2, 2017‎
The trial was part of a larger study by the Institute of Cancer Research (ICR) and the Royal Marsden NHS Foundation Trust in London. ONX-0801 enters the cancer cells by mimicking folic acid - ovarian cancer has a large number of receptors for folic acid.
 

Researchers hail 'breakthrough' drug for treating ovarian cancer

The New Daily - ‎Jun 3, 2017‎
Researchers are hailing an experimental drug as a major advance in the treatment of ovarian cancer, which typically claims the lives of up to 1400 Australian women every year. The drug, known as ONX-0801, is being described as the biggest breakthrough ...
 

Drug shrinks ovarian tumours in early trial

BBC News - ‎Jun 2, 2017‎
NHS Choices: Ovarian cancer. The researchers, from the Institute of Cancer Research and the Royal Marsden NHS Foundation Trust in London, wanted to establish whether the drug, known in the study as ONX-0801, was safe, so they tested it on a small ...
 

'Biggest breakthrough in a decade': New ovarian cancer drug proves hugely promising

RT - ‎Jun 3, 2017‎
The trial also found that because ONX-0801 targets cancer cells specifically, while leaving healthy cells alone, patients did not experience common side effects such as infections, diarrhoea, nerve damage and hair loss associated with traditional ...
 

Scientists make 'biggest breakthrough in ovarian cancer for 10 years'

Evening Standard - ‎Jun 3, 2017‎
Cancer patients who had run out of other options responded well to the new drug in a medical advance which experts have hailed as “exciting” and “promising”. The drug – called ONX-0801 – was tested on 15 woman with advanced ovarian cancer in the first ...
 

Cancer patient hails 'highly promising' new treatment after tumours shrink

ITV News - ‎Jun 3, 2017‎
A new treatment for ovarian cancer has been hailed "highly promising" by researchers after it was found to significantly shrink tumours. Seven out of 15 women with advanced ovarian cancer, who had exhausted all other treatment options, saw their ...
 

Groundbreaking new drugs give months of extra life for women suffering from ovarian cancer

Telegraph.co.uk - ‎Jun 2, 2017‎
Current efforts to combat the ovarian cancer mainly focus on targeted therapies which try to match interventions with certain gene types. But researchers say the new ONX-0801 drug has could be of benefit a wide cohort of women with advanced ovarian ...
 

This Could Be The Biggest Breakthrough In Treating Ovarian Cancer For A Decade

Refinery29 - ‎Jun 3, 2017‎
ONX-0801 works by mimicking folic acid to enter the cancer cells, and then killing them by halting the action of a protein called hymidylate synthase. Because it targets cancer cells specifically, it carries none of the side effects associated with ...
 

Ovarian cancer drug shrinks tumours in trials

The Times (subscription) - ‎Jun 2, 2017‎
Only one in three women with the cancer will survive for more than ten years and it causes 4,000 deaths a year in Britain. Scientists at the Institute of Cancer Research have developed a compound, ONX-0801, that sneaks into the tumour by disguising ...
 

New drug shrinks ovarian tumors in early trial

kwbe - ‎Jun 3, 2017‎
(CHICAGO) — A new treatment for ovarian cancer has shown “promising” results in women who are in the advanced stages of the disease, according to the BBC. The drug, known as ONX-0801, shrunk tumors in more than half the patients who participated in ...
 

Scientists develop new targeted ovarian cancer treatment with no side effects

AppsforPCdaily - ‎Jun 3, 2017‎
The team tested the drug, ONX-0801, in 15 women with ovarian cancer as part of a wider phase I clinical trial. The drug had significantly shrunk tumors in seven of the patients who carried the specific molecule that the drug was created to target. Her ...




 
dr.chan
breasthk
藥物資助
講座活動
聯絡電話:
2121 1328
聯絡地址:
Flat B, 8/F., Mow Hing Industrial Building, No.205 Wai Yip Street,
Kwun Tong, Kowloon, Hong Kong
香港觀塘偉業街205號,
茂興工業大廈8樓B室

聯絡地址:
Flat B, 8/F., Mow Hing Industrial Building,
No.205 Wai Yip Street, Kwun Tong,
Kowloon, Hong Kong
香港觀塘偉業街205號,
茂興工業大廈8樓B室
聯絡電話:
2121 1328

聯絡電郵:
info@cancerinformation.com.hk

會員註冊 | 私隱政策 | 服務條款
版權所有 不得轉載 © Copyright 2013 Cancer - information Co. All rights reserved. Powered by BIC Online